• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall V8 Serum Protein SPE Kit

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
 Class 2 Device Recall V8 Serum Protein SPE Kitsee related information
Date Initiated by FirmSeptember 14, 2026
Date PostedNovember 17, 2026
Recall Status1 Open3, Classified
Recall NumberZ-0469-2027
Recall Event ID 99987
Product Classification Electrophoretic, protein fractionation - Product Code CEF
ProductV8 Serum Protein SPE Kit, Cat. No.: 1805, containing V8 SPE Diluent, Product No.: 552512
Code Information Catalog No. 1805, Kit Lot 4-26-1805, expiration date 2028-05-31, UDI-DI: M52518050. Affected component Product No. 552512, Lot 3-26-552512
FEI Number 1618982
Recalling Firm/
Manufacturer
Helena Laboratories, Corp.
1530 Lindbergh Dr
Beaumont TX 77707-4131
For Additional Information Contact
409-842-3714
Manufacturer Reason
for Recall
Assayed quality control (QC) material (both normal and abnormal control levels) run with kits manufactured using diluent lot 3-26-552512 (a component of finished kit lot 4-26-1805) shows a reproducible shift in serum protein electrophoretic fraction distribution relative to historical/comparator diluent lots: decreased albumin (approximately 6-10 relative percentage points, roughly -0.4 to -0.55 g/dL where total protein is known) and increased beta and gamma globulin fractions (approximately +1 to +3 relative percentage points, roughly +0.05 to +0.28 g/dL). This may result in QC failures or prompt unnecessary clinical workup for hypoalbuminemia or could mask a mild true elevation in albumin, while falsely elevated beta/gamma fractions could prompt unnecessary or premature follow-up testing for suspected gammopathy.
FDA Determined
Cause 2
Component change control
ActionOn 9/14/2026, recall notices were emailed to customers who were asked to do the following: 1) Discontinue use of any remaining kits. Examine your inventory and quarantine any remaining kits. 2. Review your quality control records associated with this lot. 3. If you have supplied kits from this lot to other laboratories or sites within your organization, forward this notification to them at once so they may take the same action. 4) Complete and return the response form to technicalservice@helena.com Distributors are asked to forward the enclosed customer notification letter to each affected or potentially affected account. Advise customers to return the affected kits to you for credit and/or replacement. If you have any questions, contact the firm at technicalservice@helena.com or 1-800-231-5663 extension 1600, Monday through Friday, 8:00 AM to 5:00 PM Central Time.
Quantity in Commerce121
DistributionWorldwide - US Nationwide distribution in the states of MI, CA, TN, MS, MO, TX, IN, FL and the countries of PRY, CAN, ISR, PHL, TTO.
Total Product Life CycleTPLC Device Report

1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
-
-